Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06207032 · ClinicalTrials.gov registry record
TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
A clinical trial of Cancer, sponsored by Tempus AI.
- Recruiting
- Registry status
- 500
- Enrollment target
- 20
- Study locations
NCT06207032: Recruiting study of Cancer, sponsored by Tempus AI.
NCT06207032 is a study of Cancer that is actively recruiting participants, run by Tempus AI. The registered enrollment target is 500 participants, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06207032, a study of Cancer, is actively recruiting participants, sponsored by Tempus AI.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is a non-interventional, multicenter, multicohort evaluation of participants with cancer who will undergo longitudinal plasma ctDNA biomarker profiling at specific time points in addition to standard of care therapy.
Primary Outcome
Assess ctDNA kinetics using ctDNA clearance factors such as time to clearance, best overall clearance rate, best confirmed clearance, and time to ctDNA recurrence and correlate with standard of care therapy real-world outcomes such as overall survival, progression-free survival, time to next treatment, and time to treatment discontinuation.
Conditions Studied
Study Locations (20)
Illinois
- Southern Illinois Healthcare - Carterville
- Hope and Healing Cancer Services - Hinsdale
- Cancer Care Specialists of Illinois - O'Fallon
- Illinois Cancer Care - Peoria
- Northwest Oncology and Hematology - Rolling Meadows
Missouri
- Hannibal Regional Healthcare System, Inc. - Hannibal
- Lake Regional Health - Osage Beach
- Mosaic Life Care - Saint Joseph
- Oncology Hematology Associates - Springfield
Georgia
- Morehouse - Atlanta
- Piedmont Healthcare - Atlanta
Indiana
- Fort Wayne - Fort Wayne
- Goshen Center for Cancer Care - Goshen
Alabama
- Alabama Oncology - Birmingham
California
- PIH Health Whittier Hospital & PIH Health Physicians - Whittier
Connecticut
- Eastern CT and Hematology and Oncology Associates - Norwich
Florida
- Cancer Specialists of North Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2024-06-26 |
| Est. Completion | 2029-06-01 |
What NCT06207032 shows while recruiting
NCT06207032 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT06207032 names 20 study sites across 11 states, led by Illinois, Missouri, Georgia.
Frequently Asked Questions
What is clinical trial NCT06207032 about?
NCT06207032 is a clinical study titled "TEMPUS ARIES: A Biobank Registry Platform Study in Oncology". This study is a non-interventional, multicenter, multicohort evaluation of participants with cancer who will undergo longitudinal plasma ctDNA biomarker profiling at specific time points in addition to standard of care therapy.
What is the current status of trial NCT06207032?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2024-06-26. Estimated completion is 2029-06-01.
What conditions does trial NCT06207032 study?
This clinical trial studies the following conditions: Cancer.
Who is sponsoring clinical trial NCT06207032?
This trial is sponsored by Tempus AI, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06207032 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06207032's enrollment target sits among peer trials
500 122nd of 615 higher than 484 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI